Page last updated: 2024-11-09

pyridine-2-carbothioamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyridine-2-carbothioamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1549499
CHEMBL ID3741839
SCHEMBL ID453733
MeSH IDM0478266

Synonyms (49)

Synonym
HMS1756L09
5-22-02-00052 (beilstein handbook reference)
yn34rw97c7 ,
unii-yn34rw97c7
5346-38-3
2-pyridinethiocarboxamide
nsc-1606
nsc1606
pyridine-2-carbothioamide
amino-2-pyridylmethane-1-thione
2-thiocarbamoylpyridine
picolinothioamide
picolinic acid thioamide
thio-2-pyridinecarboxamide
nsc 1606
picolinamide, thio-
2-pyridinecarbothioamide
brn 0109733
thiopicolinamide
2-thiopicolinamide
STK035590
2-pyridylthiocarboxamide
T2618
AKOS000117022
2-pyridylthioamide
A829613
3-(pyridine-4-carbonyl)benzenesulfonyl chloride;pyridine-2-carbothioic acid amide
EN300-07638
pyridine-2-carbothioic acid amide
2-pyridinethioamide
FT-0678826
SCHEMBL453733
FG-0502
2-pyridine-carbothioamide
pyridine-2-thiocarboxamide
SY032222
mfcd00087576
2-pyridinecarbothioamide #
pyridine, 2-carbothioamide
pyridinecarbothioamide
CHEMBL3741839 ,
DTXSID90201625
J-524117
2-pyridinethioamide, 97%
CS-W002356
Z56956073
bdbm50499813
BBL100340
PD021265
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)14.40000.03403.987110.0000AID1265266
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusKic2.70000.70002.30004.3000AID1265268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1265274Inhibition of tyrosinase in mouse B16F10 cell lysates using DOPA as substrate relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265266Inhibition of mushroom tyrosinase using L-tyrosine as substrate2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265268Non-competitive inhibition of mushroom tyrosinase using L-tyrosine as substrate by Lineweaver-Burk plots analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265270Cytotoxicity against mouse B16F10 cells assessed as cell survival at 50 uM after 48 hrs by MTT assay2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265272Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 20 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265271Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 10 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265269Binding affinity to mushroom tyrosinase assessed as fluorescence quenching2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265273Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 50 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]